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INTRODUCTION
Pheochromocytomas (PCC) and paragangliomas (PGL) are 
rare chromaffin cell-derived neuroendocrine tumors of the 
adrenal medulla and extraadrenal paraganglia, respectively. The 
incidence of PCC/PGL is estimated between 2 and 5 patients 
per million per year [1] while the prevalence in hypertensive 
patients is between 0.2% and 0.6% [2]. Within this group of 
tumors, PCC make up 85% of the cases while 15%–20% are 
PGL [3]. PGL can be derived from either the parasympathetic 
or sympathetic nervous system. Parasympathetic PGL are 
usually located in the head and neck region and these tumors 
are rarely functional (<5%) [4,5]. Abdominal PGL, on the 
other hand, are predominantly sympathetic in origin and are 
located in the paraaortic and paracaval areas and around the 
inferior mesenteric artery and aortic bifurcation [4]. Some are 
also found in the duodenum, bladder, and spine. Abdominal 
PGL can produce, store and/or secrete catecholamines and 
their metabolites and produce the classic symptoms and signs 
of hypertension, palpitation, dizziness, anxiety, flushing, 
headache, and diaphoresis due to catecholamine surges. The 
hypertensive episodes and symptoms are usually paroxysmal 
in nature; hence, diagnosis may not be apparent for years as a 
result.  
The rarity of abdominal PGL has limited the number of 
publications on this subject and most are case reports and 
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Purpose: Paragangliomas (PGL) are rare neuroendocrine tumors derived from chromaffin cells of the autonomic nervous 
system. We aim to describe our experience and the long-term outcome of abdominal PGL over the last decade. 
Methods: A retrospective review of patients diagnosed with PGL in our hospital between November 2005 and June 2017 
was conducted. All nonabdominal PGL were excluded and the clinicopathological features and long-term outcomes of the 
patients were analyzed. 
Results: A total of 46 patients were diagnosed with abdominal PGL. The average age of diagnosis was 55.4 years and 
there was no sex predilection. The average tumor size was 5.85 cm and they were predominantly located in the infrarenal 
position (50%). The mean follow-up period was 42 months (range, 1.8–252 months). All patients with metastases had 
Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) of ≥4. One patient presented with synchronous metastases 
while 2 developed local recurrence and distant metastases. One presented with only local recurrence. One patient died 5 
years after diagnosis. 
Conclusion: Abdominal PGL is a rare tumor with excellent long-term prognosis. Recurrence although uncommon, can 
occur decades after initial diagnosis. Long-term follow-up is therefore recommended for all patients with PGL, especially 
in patients with PASS of ≥4.
[Ann Surg Treat Res 2020;99(6):315-319]
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literature reviews. Many series include both PCC and PGL in 
their reports. We, therefore, aim to analyze our data of PGL 
on its own and report our experience in managing this rare 
condition over the last decade at Severance Hospital, a tertiary 
referral center for endocrine surgery in Seoul. 
METHODS
We performed a retrospective review of the electronic 
medical records of all patients with the diagnosis of PGL in 
our hospital from November 2005 to June 2017. A total of 119 
patients were identified. Patients with head and neck, bladder, 
spinal, and duodenal PGL were excluded because of the vastly 
different presentation and management of these patients (Fig. 
1). Among the excluded patients, 7 were confirmed as duodenal 
paraganglioma. All of these patients were diagnosed and 
treated by endoscopic resection, thus excluded from this study. 
The remaining 46 patients with the diagnosis of abdominal PGL 
were included in the study. Their clinicopathological features 
and long-term outcomes were analyzed. Statistical analysis 
was performed using IBM SPSS Statistics software, ver. 23.0 
(IBM Corp., Armonk, NY, USA). All subjects gave their informed 
consent for inclusion before they participated in the study. The 
study was conducted in accordance with the Declaration of 
Helsinki, and the protocol was approved by the Institutional 




The mean age of diagnosis was 54.4 years, with the youngest 
patient diagnosed at 14 years (range, 14–75 years). The sex 
split was exactly 50% and none of the patients had positive 
family history. Out of the 46 patients with abdominal PGL, 
5 were diagnosed incidentally in surgical specimens from 
other abdominal surgeries. All of the 5 incidental PGL were 
diagnosed from the paraaortic soft tissue. Three were found 
during colorectal cancer surgery, 1 was found during ovarian 
cancer surgery, and the last was found during renal cancer 
surgery. Of the 41 patients, 19 had surgery at the hepatobiliary 
surgery department, 10 at urology, 7 at endocrine surgery, 2 at 
colorectal surgery, 2 at upper gastrointestinal surgery, and 1 at 
pediatric surgery. The modes of presentation are described in 
Table 1, with the tumor most commonly found incidentally on 
imaging for other reasons or health screening (n = 29). Other 
symptoms include palpitation, abdominal pain, back pain, and 
abdominal mass. Two cases were identified in the medical 
records as recurrent disease, rather than a new diagnosis of PGL 
during the study period. Preoperative hypertension (systolic 
blood pressure, >140) was present in 20 patients (43.5%) and 
12 patients received presurgical alpha blockade. Plasma and 
urinary metanephrines and catecholamines were tested in 18 
and 15 patients, respectively. Fourteen out of 18 (77.8%) were 
hormonally active tumors, with 10 patients having elevated 
normetanephrine or norepinephrine and 2 with raised levels 
of both metanephrine and normetanephrine. Two had isolated 
high serum chromogranin A, 1 with only elevated dopamine, 
and 1 with only elevated vanillylmandelic acid. Four patients 
did not have hormonally active tumors.  
Table 1. Abdominal paraganglioma patient characteristics
Characteristic Data
Patient 46 (100)
Age (yr) 55.4 (14–85)
Sex
 Male 23 (50.0)
 Female 23 (50.0)
Presenting symptom
 Incidentala) 34 (73.9)
 Abdominal pain 4 (8.7)
 Palpitation 2 (4.3)
 Back pain 1 (2.2)
 Abdominal mass 3 (6.5)
 Metastatic disease (during follow-up) 2 (4.3)
Follow-up period (mo) 42.6 (1.8–252)
Synchronous metastasis 1 (2.2)
Local recurrence + distant metastasis 2 (4.3)
Local recurrence without distant metastasis 1 (2.2)
Death 1 (2.2)
Values are presented as mean (range) or number (%). 
a)Including 5 patients with tumors found in surgical specimens for 
other surgeries.
Total number of PGL patients
(n = 119)
Excluded patients
H&N = 45, bladder = 10, spinal = 11, duodenal = 7
Total number of abdominal PGL
(n = 46)
Incidental finding




Fig. 1. Distribution of paraganglioma (PGL) patients. H&N, 
head and neck.
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Tumor characteristics and surgical approach
The average tumor size was 5.85 cm (range, 0.2–15.0 cm). 
Most of the tumors were located in the infrarenal compartment 
(inferior to the renal artery) and most were left-sided while 3 
were midline at the aortic bifurcation. Open surgical technique 
was the predominant method used to excise the tumors (n 
= 27), while the laparoscopic anterior approach was the next 
most common technique (n = 10). One case was performed 
with the laparoscopic posterior (retroperitoneal) approach. 
The Pheochromocytoma of the Adrenal Gland Scaled Score 
(PASS) was available for all 46 cases, ranging from 0 to 7. All 
the patients with local recurrence and/or metastatic disease 
had PASS of ≥4, but not all patients with PASS of ≥4 had 
recurrences (Table 2).  
Survival and recurrence outcome
The mean follow-up period was 42 months (range, 1.2–252 
months). One patient presented with synchronous metastasis 
while 3 others developed recurrent diseases. One patient 
presented with only local recurrence 2 years after the initial 
surgery while the other 2 patients had both local and distant 
recurrences, one after 3 years and the other after 19 years. One 
patient died 5 years after presentation. 
DISCUSSION
Abdominal PGL are rare tumors, highlighted by the fact 
that only 46 patients were treated at our hospital over the last 
decade, despite our hospital being a large tertiary referral center 
for endocrine surgery. Our results are consistent with other 
published data with regard to the roughly equal sex distribution 
[1,6,7] and the mean age of diagnosis in the 5th decade, 
particularly in the sporadic form of the disease [3]. 
The classic presentation of PCC/PGL is related to intermittent 
surges of catecholamine resulting in symptoms such as 
palpitation, headache, and flushing. However, contrary to other 
publications [3], our patients mostly presented incidentally. This 
could be related to the high rates of CT scans performed as part 
of health screening in South Korea. Though imaging modalities 
become more sophisticated and cheaper to obtain, the pattern 
of presentation would become increasingly incidental rather 
than symptom related. This trend is not unique to PGL, but also 
all other medical conditions.
According to the Endocrine Society clinical practice guidelines 
on management of pheochromocytomas and PGL published in 
2014 [2], the initial testing for PCC/PGL should include plasma 
free metanephrines or urinary fractionated metanephrines. 
Unfortunately, in our patient population, only 18 patients had 
these blood tests done. The reason for this is not very clear 
from the medical records, but we presume that the tests were 
not performed because not all patients were managed by an 
endocrinology team and many of the patients did not present 
with the classic symptoms. Fortunately, this did not result in 
any adverse outcome in terms of blood pressure management 
perioperatively. This highlights that a strong clinical suspicion 
of PGL should be present when dealing with retroperitoneal 
tumors located close to the midline in the abdomen, regardless 
of whether the classic symptoms are present.
The location of PGL close to or at the midline is due to 
its origin, being derived from the sympathetic chain in the 
abdomen and pelvis. Our patients predominantly had tumors 
located to the left of midline, which is similar to other studies 
[7,8]. This is, however, not a regularly reported finding, and the 
laterality of PGL is still equivocal.
The surgical approach of PGL is quite variable depending on 
the size, location, suspicion of malignancy, and surgeon skill. 
In our study, most operations were performed with the open 
approach, followed by the laparoscopic transperitoneal anterior 
approach. All tumors less than 7 cm were resected with the 
Table 2. Clinicopathological features of the tumors and 
operative approach
Variable Data





Others (incidental finding) 5 (10.9)
Site
Aortic bifurcation 3 (6.5)
Suprarenal 13 (28.3)
Infrarenala) 23 (50.0)
Supra- and infrarenalb) 4 (8.7)
Pancreatic 2 (4.3)
Unknown 1 (2.2)
Operative approach (n = 39)c)
Open 27 (69.2)
Laparoscopic anterior 10 (25.6)
Laparoscopic posterior 1 (2.6)
Laparoscopic converted to open 1 (2.6)
PASS (n = 46)
0–3 (n = 35)
  No recurrence 35 (100)
  Recurrence 0 (0)
4–7 (n = 11)
  No recurrence    8 (72.7)
  Recurrence/metastasis 3 (27.3)
Values are presented as mean ± standard deviation (range) or 
number (%).  
PASS, Phaeochromocytoma of the Adrenal Gland Scaled Score.
a)One infrarenal tumor encasing the aorta. b)One supra- and 
infrarenal tumor encasing the inferior vena cava. c)Excluding 5 
patients with incidental finding of tumor in non-paragangliomas 
surgery and 2 nonoperative cases. 
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open approach apart from one 10-cm tumor which was resected 
with the laparoscopic anterior approach. The reason for the 
higher open approach as opposed to a minimally invasive 
technique could be because referrals in our hospital are made to 
surgeons from different specialties such as endocrine surgeons, 
hepatobiliary surgeons, and urologists, depending on the 
location of the tumors rather than a streamlined referral to 1 
specialty. With the smaller number of cases per surgeon, many 
surgeons would have felt more comfortable approaching these 
tumors via the open technique as the locations of these tumors 
can be very challenging. The most difficult tumors would be 
large tumors located in the aortocaval space and those adherent 
to or encasing major vessels such as the aorta, inferior vena 
cava, and renal vessels. However, as surgeons become more 
comfortable with laparoscopic transperitoneal or retroperitoneal 
adrenal surgeries, small PGL can be safely resected with 
minimally invasive techniques [8-12]. The retroperitoneal 
approach also has the added advantage of not entering the 
peritoneal space hence reducing the potential injury to adjacent 
organs such as the liver, duodenum, stomach, spleen, and 
pancreas. This approach is also useful in patients who have had 
previous abdominal surgeries, and hence abdominal adhesions.
The pathological diagnosis of PGL is made in the presence 
of the classic feature of cell nests arranged in the Zellballen 
pattern separated by fibrovascular stroma and surrounded by 
sustentacular cells. The cells are typically polygonal or oval-
shaped and stain positive for chromogranin A, synaptophysin, 
neuron-specific enolase, and CD56. Sustentacular cells are 
usually S100 positive [13,14]. To differentiate it from other 
neural origin tumors, PGL usually stain negative for MelanA, 
inhibin, keratin, and calretinin. On the other hand, the 
diagnosis of malignancy cannot be made based on any one or 
more histopathological criteria alone. Malignancy is defined 
as the presence of tumors in sites that do not usually contain 
chromaffin cells, i.e., evidence of metastasis [4]. Several 
scoring systems have identified factors that increase the risk 
of malignancy. One such scoring system is the PASS which 
was developed by Thompson [14] in 2002. This score has 
been widely used internationally, including in our hospital. 
Thompson proposed that a score of ≥4 increases a patient’s risk 
of developing metastasis. In our cohort of patients, all patients 
with metastasis and/or local recurrence had PASS of ≥4. 
However, not all patients with scores of ≥4 recurred. This is 
consistent with Thompson’s study where 17 out of 50 patients 
who had histologically “malignant” features had not developed 
clinical metastasis during his study period [14]. Other authors 
have also not been able to validate the accuracy of PASS [15,16]. 
The other scoring system in use currently is the Grading System 
for Adrenal Pheochromocytoma and Paraganglioma (GAPP), 
proposed by Kimura et al. [17] in 2014. The main difference 
between GAPP and PASS is the inclusion of the type of 
catecholamine secreted by the tumor and the Ki67 index. Only 
norepinephrine secretion scores a point, while nonfunctioning 
and epinephrine secreting tumors have zero scores. However, 
because this is a relatively new scoring system, the GAPP 
scores have not been reported by our pathologists. This scoring 
system, however, has been validated by Koh et al. [16] in 2017, 
and these authors have also included mutation in the succinate 
dehydrogenase (SDH) type B to obtain a modified GAPP score, 
which was predictive of metastasis. 
In our patient population, the mean follow-up period was 
42.6 months, with the longest follow-up period of 252 months 
in a patient with local and distant recurrence after 19 years. 
This patient is still alive with the disease after 21 years. The 
other 2 recurrences occurred 2 and 3 years after their initial 
diagnoses. This demonstrates the highly variable disease 
pattern, with recurrence possible decades after the initial 
diagnosis. The disease-specific mortality is also low, with only 1 
death reported out of a total of 46 patients over the 11.5 years of 
the study period.
The limitation of this study is its retrospective design. The 
most significant omission is the genetic profile of patients, as 
up to 60% of PCC/PGL cases may have a germline or somatic 
mutation [1]. Associated mutations are located in the von 
Hippel Lindau (VHL), SDH complex (SDHx: SDHA, SDHB, SDHC, 
and SDHD; SDH5/SDHAF2), neurofibromin 1 (NF1), rearranged 
during transfection photo oncogene (RET), transmembrane 
protein 127 (TMEM 127), Myc associated factor X (MAX), and 
menin (MEN1) genes [1,2,5]. Mutation in the SDHB gene has 
been linked to high rates of malignancy of 40% or more [2]. 
Large prospective studies investigating the link between genetic 
mutation and long-term survival and recurrence would be 
useful to risk stratify patients and tailor the intensity of follow-
up for patients.
Abdominal PGL are rare tumors with excellent prognosis. 
However, given that recurrence can occur more than a decade 
after diagnosis, long-term follow-up is essential, especially for 
patients with PASS of ≥4.
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